Saturday 17 October 2026
Export STXS’s income statement to Excel — free account
Stereotaxis Inc.
STXS Healthcare Medical Instruments & Supplies
Stereotaxis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $32.4 million, up 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 12.8%, EPS was flat and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.01
0.04
−3.81%
Follow STXS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.72 | 5.83 | 6.46 | 9.52 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(46.82) | (52.86) | (52.71) | (68.07) | |
P/B ratio |
14.05 | 12.67 | 15.52 | 45.67 | |
Price to Tangible BV |
68.22 | 41.35 | 63.63 | 0.00 | |
EV/Sales |
5.48 | 5.47 | 6.15 | 9.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(10.78) | (11.11) | (14.54) | (33.01) | |
EV/FCF |
(10.63) | (10.99) | (14.44) | (32.87) | |
Quick Ratio |
0.91 | 1.05 | 1.05 | 0.78 | |
Current Ratio |
1.42 | 1.56 | 1.51 | 1.31 | |
Net Debt/EBITDA |
2.52 | 2.62 | 2.55 | 1.70 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.62 | 0.63 | 0.65 | 0.62 | |
Operating CF/Net income |
0.77 | 0.56 | 0.68 | 0.62 | |
Capex/Depreciation |
(0.16) | (0.20) | (0.18) | 0.00 | |
Research and Development Expense of Revenue |
31.16% | 38.10% | 31.35% | 34.11% | |
Selling, General and Administrative Expense of Revenue |
86.88% | 117.28% | 84.07% | 108.68% | |
Intangible Assets out of Total Assets |
0.17 | 0.18 | 0.20 | 0.23 | |
Share Based Compensation of Revenue |
20.96% | 33.54% | 28.31% | 33.53% | |
Graham Net Nets |
0.00 | 0.01 | 0.00 | (0.03) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(13.95%) | (13.04%) | (10.87%) | (9.00%) | |
Free Cash Flow Yield |
(9.01%) | (8.53%) | (6.59%) | (2.97%) | |
Revenue per Share |
0.08 | 0.06 | 0.10 | 0.08 | |
Operating CF per Share |
(0.04) | (0.03) | (0.04) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.04) | (0.04) | (0.04) | (0.05) | |
Cash per Share |
0.10 | 0.15 | 0.15 | 0.11 | |
Shareholders Equity per Share |
0.17 | 0.20 | 0.21 | 0.13 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.17 | 0.20 | 0.21 | 0.13 | |
Free Cash Flow |
(3.74) | (3.52) | (4.04) | (4.20) | |
Working Capital |
11.19 | 12.94 | 11.49 | 6.29 | |
Capital Expenditures |
(0.06) | (0.08) | (0.07) | 0.00 | |
Net Current Asset Value |
(0.12) | 1.60 | 0.32 | (7.39) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.13 | 6.97 | 6.99 | 6.63 | |
Average Payables |
6.80 | 5.68 | 5.22 | 5.54 | |
Average Inventory |
11.06 | 10.15 | 8.95 | 9.58 | |
Average Assets |
48.38 | 49.87 | 49.49 | 48.26 | |
Average Common Equity |
6.85 | 8.62 | 9.78 | 8.54 |
Columns are period end dates